You are here

Epidiolex

These Epilepsy Drugmakers Are About to Brawl

These Epilepsy Drugmakers Are About to Brawl

Motley Fool

Flag link:

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Xconomy

Dravet syndrome

clinical trials

Flag link:

Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana

Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana

San Francisco Chronicle, CA

clinical trials

Flag link:

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

CP Wire

Flag link:

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

Flag link:

FDA just approved the first prescription drug derived from marijuana: 4 outstanding questions

FDA just approved the first prescription drug derived from marijuana: 4 outstanding questions

Medical Marketing and Media

Flag link:

FDA approves country’s first medicine made from marijuana

FDA approves country’s first medicine made from marijuana

Stat

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

3 Biotechs With Huge FDA Decisions in June

3 Biotechs With Huge FDA Decisions in June

Motley Fool

Array Biopharma

Flag link:

This Cannabis-Based Drug Is On the Verge of Making History

This Cannabis-Based Drug Is On the Verge of Making History

Motley Fool

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US

A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US

CP Wire

Flag link:

FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy

FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy

Forbes

advisory panels

Flag link:

GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval

GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval

Fierce Biotech

Flag link:

3 Biotechs That Could Get Big Boosts in April

3 Biotechs That Could Get Big Boosts in April

Motley Fool

Neurocrine Biosciences

Flag link:

3 Blockbuster Drug Launches to Watch In 2018

3 Blockbuster Drug Launches to Watch In 2018

Motley Fool

Gilead Sciences

Flag link:

GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures

GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures

Endpoints

clinical trials

Flag link:

A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy

A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy

Motley Fool

Flag link:

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Motley Fool

Dravet syndrome

Flag link:

GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy

GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy

Xtalks

clinical trials

Dravet syndrome

Flag link:

Pages